Vitasora Health (VHL) H1 2026 earnings summary

Executive summary

• Expanded patient programs to 22,880 by 31 December 2025, with 1,600 new enrollments in the December quarter, reflecting growth in the U.S. connected care segment.

• Improved billing productivity, with daily clinical billing up 14% in October and 22% in December compared to September 2025; run-rate entering January 2026 was over 50% higher than September.

• Completed transition from legacy patients, positioning for stable growth in the second half of FY2026.

• Technology platform upgrades and AI enablement underway to support larger patient volumes and operational efficiency.

Financial highlights

• Operating revenue for the half-year was $2.30 million, up from $0.93 million year-over-year; total revenue including R&D tax incentive reached $2.85 million.

• Net loss after tax was $5.13 million, compared to $3.64 million loss in the prior year period.

• Customer cash receipts totaled $2.06 million, with net cash used in operating activities at $5.78 million; December quarter operating cash outflows improved by 28% versus September quarter.

• Basic and diluted loss per share were $(0.29), compared to $(0.30) in the prior year.

Outlook and guidance

• Substantial embedded pipeline within existing accounts and strong late-stage new client negotiations.

• Regulatory tailwinds from reimbursement reforms effective 1 January 2026, expected to boost revenue per patient and reimbursement rates.

• Technology and AI upgrades scheduled for early Q2 CY2026, anticipated to enhance scalability and operational leverage.

• Management expects continued enrolment and revenue growth, subject to patient engagement, staffing, and market conditions.